IL-36 antagonism blunts the proliferation and migration of oral squamous cell carcinoma cells
Zihui Li,Xiaoxin Zhang,Ke Li,Fuyan Li,Jiahao Kou,Yuhan Wang,Xiaoyue Wei,Yawei Sun,Yue Jing,Yuxian Song,QiuYa Yu,Haijia Yu,Shuai Wang,Shi Chen,Yangtin Wang,Simin Xie,Xiangyang Zhu,Yifan Zhan,Guowen Sun,Yanhong Ni
DOI: https://doi.org/10.1016/j.cellsig.2024.111096
Abstract:IL-36 is known to mediate inflammation and fibrosis. Nevertheless, IL-36 signalling axis has also been implicated in cancer, although understanding of exact contribution of IL-36 to cancer progression is very limited, partly due to existence of multiple IL-36 ligands with agonistic and antagonistic function. Here we explored the role of IL-36 in oral squamous cell carcinoma (OSCC). Firstly, we analyzed expression of IL-36 ligands and receptor and found that the expression of IL-36γ was significantly higher in head and neck cancer (HNSCC) than that of normal tissues, and that the high expression of IL-36γ predicted poor clinical outcomes. Secondly, we investigated the direct effect of IL-36γ on OSCC cells and found that IL-36γ stimulated proliferation of OSCC cells with high expression of IL-36R expression. Interestingly, IL-36γ also promoted migration of OSCC cells with low to high IL-36R expression. Critically, both proliferation and migration of OSCC cells induced by IL-36γ were abrogated by anti-IL-36R mAb. Fittingly, RNA sequence analysis revealed that IL-36γ regulated genes involved in cell cycle and cell division. In summary, our results showed that IL-36γ can be a tumor-promoting factor, and targeting of IL-36R signalling may be a beneficial targeted therapy for patients with abnormal IL-36 signalling.